Multiple anti-ischemic stroke-related proteins

Multiple anti-ischemic stroke-related proteins is a collective term used to describe a heterogeneous group of molecular targets involved in the pathogenesis and treatment of ischemic stroke. This group encompasses a wide array of proteins, including enzymes responsible for clot dissolution like tissue-type plasminogen activator (tPA), receptors that mediate neuronal injury such as the N-methyl-D-aspartate (NMDA) receptor, and various signaling molecules involved in neuroinflammation and programmed cell death (Herpich & Rincon, 2020). In modern drug discovery, particularly within network pharmacology, this term is often employed to categorize the multiple nodes in a biological network that a single drug or a combination of compounds might influence to provide neuroprotection or improve functional recovery (Lu et al., 2020). Because the ischemic cascade involves a rapid succession of energy failure, excitotoxicity, and oxidative stress, targeting a single protein is often insufficient, leading researchers to focus on this broader set of proteins. As such, this entry does not represent a single therapeutic target but rather a functional category of proteins relevant to the multi-faceted nature of stroke pathology.

Other names

Anti-ischemic stroke targetsStroke-related proteinsIschemic stroke therapeutic targets

The mechanisms of action are diverse and depend on the specific protein targeted within the group; they include the conversion of plasminogen to plasmin for thrombolysis (e.g., tPA), the inhibition of platelet aggregation (e.g., P2Y12 inhibitors), and the scavenging of free radicals to prevent neuronal damage (e.g., Edaravone) (Herpich & Rincon, 2020).